Predictors of cardiovascular autonomic neuropathy onset and progression in a cohort of type 1 diabetic patients

Autores
Matta, M.; Pavy Le Traon, Anne; Pérez Lloret, Santiago; Laporte, C.; Berdugo, I.; Nasr, N.; Hanaire, H.; Senard, J. M.
Año de publicación
2018
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Aim. The prevalence of cardiovascular autonomic neuropathy (CAN) in diabetes mellitus is well documented. However, the rate and predictors of both the development and progression of CAN have been less studied. Hereby, we assessed the rate and the major risk factors for CAN initiation and progression in a cohort of type 1 diabetic patients followed over a three-year period. Methods. 175 type 1 diabetic patients (mean age: 50 ± 11 years; female/male: 76/99) with positive bedside screening for CAN were included and underwent 2 standardized autonomic testings using 4 standardized tests (deep breathing, Valsalva maneuver, 30/15 ratio, and changes in blood pressure during standing), separated by 3 ± 1 years. CAN staging was achieved according to the Toronto Consensus Panel on Diabetic Autonomic Neuropathy into 4 categories: absent, possible, confirmed, or severe CAN. Results. Out of the 175 patients included, 31.4% were free of CAN, 34.2% had possible CAN, 24.6% had confirmed CAN, and 9.7% exhibited severe CAN at the first assessment. Among the 103 patients with nonsevere CAN at inclusion, forty-one (39.8%) had an increase of at least one category when reassessed and 62 (60.2%) remained stable. A bivariate analysis indicated that only BMI and exposure to selective serotonin reuptake inhibitors (SSRIs) were significantly different in both groups. A multivariate analysis indicated that lower BMI (OR: 0.15, CI 95%: 0.05-0.48, p = 0 003) and SSRI exposure (OR: 4.18, CI 95%: 1.03-16.97, p = 0 04) were the sole predictors of CAN deterioration. In the 55 patients negative for CAN at the first laboratory assessment, 12 became positive at the second assessment. Conclusion. No clear predictive factor for CAN onset was identified. However, once present, CAN progression was related to low BMI and SSRI exposure.
Fil: Matta, M.. Centre Hospitalier Universitaire de Toulouse; Francia
Fil: Pavy Le Traon, Anne. Institut des Maladies Métaboliques et Cardiovasculaires; Francia. Hôpital Pierre-Paul Riquet; Francia
Fil: Pérez Lloret, Santiago. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Cardiológicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Cardiológicas; Argentina
Fil: Laporte, C.. Centre Hospitalier Universitaire de Toulouse; Francia
Fil: Berdugo, I.. Centre Hospitalier Universitaire de Toulouse; Francia
Fil: Nasr, N.. Hôpital Pierre-Paul Riquet; Francia. Institut des Maladies Métaboliques et Cardiovasculaires; Francia
Fil: Hanaire, H.. Centre Hospitalier Universitaire de Toulouse; Francia
Fil: Senard, J. M.. Centre Hospitalier Universitaire de Toulouse; Francia. Institut des Maladies Métaboliques et Cardiovasculaires; Francia
Materia
autonomic neuropathy
diabetes
progression
predictors
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/97056

id CONICETDig_c1631bc71d1e8358bceafed77c6b0236
oai_identifier_str oai:ri.conicet.gov.ar:11336/97056
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Predictors of cardiovascular autonomic neuropathy onset and progression in a cohort of type 1 diabetic patientsMatta, M.Pavy Le Traon, AnnePérez Lloret, SantiagoLaporte, C.Berdugo, I.Nasr, N.Hanaire, H.Senard, J. M.autonomic neuropathydiabetesprogressionpredictorshttps://purl.org/becyt/ford/3.2https://purl.org/becyt/ford/3Aim. The prevalence of cardiovascular autonomic neuropathy (CAN) in diabetes mellitus is well documented. However, the rate and predictors of both the development and progression of CAN have been less studied. Hereby, we assessed the rate and the major risk factors for CAN initiation and progression in a cohort of type 1 diabetic patients followed over a three-year period. Methods. 175 type 1 diabetic patients (mean age: 50 ± 11 years; female/male: 76/99) with positive bedside screening for CAN were included and underwent 2 standardized autonomic testings using 4 standardized tests (deep breathing, Valsalva maneuver, 30/15 ratio, and changes in blood pressure during standing), separated by 3 ± 1 years. CAN staging was achieved according to the Toronto Consensus Panel on Diabetic Autonomic Neuropathy into 4 categories: absent, possible, confirmed, or severe CAN. Results. Out of the 175 patients included, 31.4% were free of CAN, 34.2% had possible CAN, 24.6% had confirmed CAN, and 9.7% exhibited severe CAN at the first assessment. Among the 103 patients with nonsevere CAN at inclusion, forty-one (39.8%) had an increase of at least one category when reassessed and 62 (60.2%) remained stable. A bivariate analysis indicated that only BMI and exposure to selective serotonin reuptake inhibitors (SSRIs) were significantly different in both groups. A multivariate analysis indicated that lower BMI (OR: 0.15, CI 95%: 0.05-0.48, p = 0 003) and SSRI exposure (OR: 4.18, CI 95%: 1.03-16.97, p = 0 04) were the sole predictors of CAN deterioration. In the 55 patients negative for CAN at the first laboratory assessment, 12 became positive at the second assessment. Conclusion. No clear predictive factor for CAN onset was identified. However, once present, CAN progression was related to low BMI and SSRI exposure.Fil: Matta, M.. Centre Hospitalier Universitaire de Toulouse; FranciaFil: Pavy Le Traon, Anne. Institut des Maladies Métaboliques et Cardiovasculaires; Francia. Hôpital Pierre-Paul Riquet; FranciaFil: Pérez Lloret, Santiago. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Cardiológicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Cardiológicas; ArgentinaFil: Laporte, C.. Centre Hospitalier Universitaire de Toulouse; FranciaFil: Berdugo, I.. Centre Hospitalier Universitaire de Toulouse; FranciaFil: Nasr, N.. Hôpital Pierre-Paul Riquet; Francia. Institut des Maladies Métaboliques et Cardiovasculaires; FranciaFil: Hanaire, H.. Centre Hospitalier Universitaire de Toulouse; FranciaFil: Senard, J. M.. Centre Hospitalier Universitaire de Toulouse; Francia. Institut des Maladies Métaboliques et Cardiovasculaires; FranciaHindawi Publishing Corporation2018-03info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/97056Matta, M.; Pavy Le Traon, Anne; Pérez Lloret, Santiago; Laporte, C.; Berdugo, I.; et al.; Predictors of cardiovascular autonomic neuropathy onset and progression in a cohort of type 1 diabetic patients; Hindawi Publishing Corporation; Journal of Diabetes Research; 2018; 3-2018; 1-8; 56013512314-6745CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://www.hindawi.com/journals/jdr/2018/5601351/info:eu-repo/semantics/altIdentifier/doi/10.1155/2018/5601351info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-03T09:58:03Zoai:ri.conicet.gov.ar:11336/97056instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-03 09:58:03.72CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Predictors of cardiovascular autonomic neuropathy onset and progression in a cohort of type 1 diabetic patients
title Predictors of cardiovascular autonomic neuropathy onset and progression in a cohort of type 1 diabetic patients
spellingShingle Predictors of cardiovascular autonomic neuropathy onset and progression in a cohort of type 1 diabetic patients
Matta, M.
autonomic neuropathy
diabetes
progression
predictors
title_short Predictors of cardiovascular autonomic neuropathy onset and progression in a cohort of type 1 diabetic patients
title_full Predictors of cardiovascular autonomic neuropathy onset and progression in a cohort of type 1 diabetic patients
title_fullStr Predictors of cardiovascular autonomic neuropathy onset and progression in a cohort of type 1 diabetic patients
title_full_unstemmed Predictors of cardiovascular autonomic neuropathy onset and progression in a cohort of type 1 diabetic patients
title_sort Predictors of cardiovascular autonomic neuropathy onset and progression in a cohort of type 1 diabetic patients
dc.creator.none.fl_str_mv Matta, M.
Pavy Le Traon, Anne
Pérez Lloret, Santiago
Laporte, C.
Berdugo, I.
Nasr, N.
Hanaire, H.
Senard, J. M.
author Matta, M.
author_facet Matta, M.
Pavy Le Traon, Anne
Pérez Lloret, Santiago
Laporte, C.
Berdugo, I.
Nasr, N.
Hanaire, H.
Senard, J. M.
author_role author
author2 Pavy Le Traon, Anne
Pérez Lloret, Santiago
Laporte, C.
Berdugo, I.
Nasr, N.
Hanaire, H.
Senard, J. M.
author2_role author
author
author
author
author
author
author
dc.subject.none.fl_str_mv autonomic neuropathy
diabetes
progression
predictors
topic autonomic neuropathy
diabetes
progression
predictors
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.2
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Aim. The prevalence of cardiovascular autonomic neuropathy (CAN) in diabetes mellitus is well documented. However, the rate and predictors of both the development and progression of CAN have been less studied. Hereby, we assessed the rate and the major risk factors for CAN initiation and progression in a cohort of type 1 diabetic patients followed over a three-year period. Methods. 175 type 1 diabetic patients (mean age: 50 ± 11 years; female/male: 76/99) with positive bedside screening for CAN were included and underwent 2 standardized autonomic testings using 4 standardized tests (deep breathing, Valsalva maneuver, 30/15 ratio, and changes in blood pressure during standing), separated by 3 ± 1 years. CAN staging was achieved according to the Toronto Consensus Panel on Diabetic Autonomic Neuropathy into 4 categories: absent, possible, confirmed, or severe CAN. Results. Out of the 175 patients included, 31.4% were free of CAN, 34.2% had possible CAN, 24.6% had confirmed CAN, and 9.7% exhibited severe CAN at the first assessment. Among the 103 patients with nonsevere CAN at inclusion, forty-one (39.8%) had an increase of at least one category when reassessed and 62 (60.2%) remained stable. A bivariate analysis indicated that only BMI and exposure to selective serotonin reuptake inhibitors (SSRIs) were significantly different in both groups. A multivariate analysis indicated that lower BMI (OR: 0.15, CI 95%: 0.05-0.48, p = 0 003) and SSRI exposure (OR: 4.18, CI 95%: 1.03-16.97, p = 0 04) were the sole predictors of CAN deterioration. In the 55 patients negative for CAN at the first laboratory assessment, 12 became positive at the second assessment. Conclusion. No clear predictive factor for CAN onset was identified. However, once present, CAN progression was related to low BMI and SSRI exposure.
Fil: Matta, M.. Centre Hospitalier Universitaire de Toulouse; Francia
Fil: Pavy Le Traon, Anne. Institut des Maladies Métaboliques et Cardiovasculaires; Francia. Hôpital Pierre-Paul Riquet; Francia
Fil: Pérez Lloret, Santiago. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Cardiológicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Cardiológicas; Argentina
Fil: Laporte, C.. Centre Hospitalier Universitaire de Toulouse; Francia
Fil: Berdugo, I.. Centre Hospitalier Universitaire de Toulouse; Francia
Fil: Nasr, N.. Hôpital Pierre-Paul Riquet; Francia. Institut des Maladies Métaboliques et Cardiovasculaires; Francia
Fil: Hanaire, H.. Centre Hospitalier Universitaire de Toulouse; Francia
Fil: Senard, J. M.. Centre Hospitalier Universitaire de Toulouse; Francia. Institut des Maladies Métaboliques et Cardiovasculaires; Francia
description Aim. The prevalence of cardiovascular autonomic neuropathy (CAN) in diabetes mellitus is well documented. However, the rate and predictors of both the development and progression of CAN have been less studied. Hereby, we assessed the rate and the major risk factors for CAN initiation and progression in a cohort of type 1 diabetic patients followed over a three-year period. Methods. 175 type 1 diabetic patients (mean age: 50 ± 11 years; female/male: 76/99) with positive bedside screening for CAN were included and underwent 2 standardized autonomic testings using 4 standardized tests (deep breathing, Valsalva maneuver, 30/15 ratio, and changes in blood pressure during standing), separated by 3 ± 1 years. CAN staging was achieved according to the Toronto Consensus Panel on Diabetic Autonomic Neuropathy into 4 categories: absent, possible, confirmed, or severe CAN. Results. Out of the 175 patients included, 31.4% were free of CAN, 34.2% had possible CAN, 24.6% had confirmed CAN, and 9.7% exhibited severe CAN at the first assessment. Among the 103 patients with nonsevere CAN at inclusion, forty-one (39.8%) had an increase of at least one category when reassessed and 62 (60.2%) remained stable. A bivariate analysis indicated that only BMI and exposure to selective serotonin reuptake inhibitors (SSRIs) were significantly different in both groups. A multivariate analysis indicated that lower BMI (OR: 0.15, CI 95%: 0.05-0.48, p = 0 003) and SSRI exposure (OR: 4.18, CI 95%: 1.03-16.97, p = 0 04) were the sole predictors of CAN deterioration. In the 55 patients negative for CAN at the first laboratory assessment, 12 became positive at the second assessment. Conclusion. No clear predictive factor for CAN onset was identified. However, once present, CAN progression was related to low BMI and SSRI exposure.
publishDate 2018
dc.date.none.fl_str_mv 2018-03
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/97056
Matta, M.; Pavy Le Traon, Anne; Pérez Lloret, Santiago; Laporte, C.; Berdugo, I.; et al.; Predictors of cardiovascular autonomic neuropathy onset and progression in a cohort of type 1 diabetic patients; Hindawi Publishing Corporation; Journal of Diabetes Research; 2018; 3-2018; 1-8; 5601351
2314-6745
CONICET Digital
CONICET
url http://hdl.handle.net/11336/97056
identifier_str_mv Matta, M.; Pavy Le Traon, Anne; Pérez Lloret, Santiago; Laporte, C.; Berdugo, I.; et al.; Predictors of cardiovascular autonomic neuropathy onset and progression in a cohort of type 1 diabetic patients; Hindawi Publishing Corporation; Journal of Diabetes Research; 2018; 3-2018; 1-8; 5601351
2314-6745
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://www.hindawi.com/journals/jdr/2018/5601351/
info:eu-repo/semantics/altIdentifier/doi/10.1155/2018/5601351
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Hindawi Publishing Corporation
publisher.none.fl_str_mv Hindawi Publishing Corporation
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1842269498205274112
score 13.13397